Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece
Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22818870

DOI
10.1016/j.clinthera.2012.07.002

Original Paper URL
Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece

Indexing Status
Subject indexing assigned by NLM

MeSH
Benzazepines /economics /therapeutic use; Bupropion /economics /therapeutic use; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Drug Costs; Greece /epidemiology; Health Care Costs; Humans; Insurance, Health, Reimbursement /economics; Markov Chains; Models, Economic; Monte Carlo Method; Prevalence; Quality-Adjusted Life Years; Quinoxalines /economics /therapeutic use; Smoking /economics /mortality /prevention & control; Smoking Cessation /economics; Time Factors; Tobacco Use Cessation Products /economics; Tobacco Use Disorder /economics /mortality /therapy; Treatment Outcome; Varenicline

AccessionNumber
22012031588

Date bibliographic record published
06/02/2013